Synthematix, which provides software for creating chemistry workflow environments, recently named three new members to the company’s board of directors.

David Floyd is the former vice president of discovery chemistry at Bristol-Myers Squibb with responsibilities for 400 staff in four research sites in North America. Floyd was also responsible for establishing external drug discovery and technology alliances with groups in the U.S., Europe and India. He is currently a consultant and sits on numerous scientific advisory boards.

Kazumi Shiosaki is the entrepreneur in residence at MPM Capital, a position she has held since 2001. Previously, Shiosaki was senior VP of scientific development and senior VP of drug discovery at Millennium Pharmaceuticals. She also has managed research programs at Abbott Labs before joining Millennium and serves on the boards of several private companies.

Jason Caplain is a partner with Southern Capitol Ventures. Previously, Caplain spent two years at Red Hat, where he held a lead role in the company’s finance and operations group, and assisted with the successful IPO. Prior to Red Hat, Caplain was a partner at the consulting firm of Harrison Hurley and Co.

“These outstanding individuals are joining our board of directors because they share our vision for improving the way that chemical research and development is conducted,” according to CEO Steve Jones. “Synthematix’s flagship product, the Arthur Suite, is on the forefront of creating a comprehensive chemistry workflow environment for synthetic chemists that works in concert with other software important to the research enterprise.”